睿丰康生物医药科技有限公司以抗病毒、抗肿瘤、中西医结合免疫调节新药研发，高端个性化基因、细胞及免疫功能检测为核心，致力于打造集预防医疗服务、抗病毒、抗肿瘤免疫治疗、医学检验、健康管理一体化发展的预防医学健康医学基地。公司的主要创始人团队有着多年分子生物学、病毒学、免疫学、肿瘤治疗和转化医学专业经验，是肿瘤免疫治疗领域里病毒载体与细胞疗法的先驱，拥有多项自主知识产权的核心技术，取得了一系列具有国际领先地位和一流水平的创新成果。公司已与多家生物技术、医药企业，以及疾控中心等机构建立了战略合作关系，共同开发预防型和治疗型mVSV-Vac载体疫苗，以及开展基于dR-VSV-Px假病毒系列检测评价抗病毒中和抗体在疫苗接种与疾病预防中的应用。
 
Fantasia BioPharma Inc. is focusing on the discovery and development of innovative anti-viral, anti-tumor and TMC-derived immune modulating drugs, in addition to novel personalized clinical testing and diagonosis based on gene, cell and immuno functions. The long-term goal of the company is to build a world-class regional center for preventive and health medical sciences with integrated business activities in health management, medical consultation, clinical diagnostics, out-patient services, and novel immunotherapy and treatment against cancer and viral diseases. The team members and its scientific advisers are world renowned experts and leaders with broad and years of experiences in molecular biology, virology, immunology, cancer therapy and their clinical translation. As one of the pioneer in the filed, the company has been granted with a battery of critical patents in immunodiagnostics and cancer immunotherapy employing viral vector-mediated genetic manipulation. The unique profile and achievement of the company has led to the formation of several highly significant alliance and partnership with multiple biotech, diagnostic and pharmaceutical companies, as well as government disease control agencies (CDC) to co-develop therapeutic and prophylatic vaccines based on its mVSV-Vac platform, and neutralization antibody testing and disease protection evaluation utilizing dR-VSV-Px pseudotyped reporter virus system for populations have been vaccinated with COVID-19 vaccines.